Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
复制标题
DOI：
10.1093/cid/ciz942
复制
发表时间：
2020-04-15
影响因子：
11.8
通讯作者：
Migliori, Giovanni Battista
中科院分区：
文献类型：
--
作者：
Alffenaar, Jan-Willem C.;Gumbo, Tawanda;Migliori, Giovanni Battista
消除结核病需要创新的方法。新的全球结核病网络（GTN）旨在利用多学科、多部门方法，对消除结核病领域尚未满足的关键治疗和诊断需求进行研究。新GTN中的结核病药理学部分旨在检测和研究当前的知识差距，使用通过临床前感染系统获得的人体药代动力学测试潜在的解决方案，并将这些发现返回给床边。此外，这种方法将允许前瞻性地识别和验证新方案的最佳较短治疗持续时间。当优先考虑以人为本的方法时，使用现有和重新用途的药物进行优化治疗可能会产生更大的影响，并承认年龄，性别，合并症以及社会和计划环境的重要性。在这篇观点文章中，我们就结核病药理学和相关策略如何有助于消除结核病进行了深入的讨论。
Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination using multidisciplinary, multisectorial approaches. The TB Pharmacology section within the new GTN aims to detect and study the current knowledge gaps, test potential solutions using human pharmacokinetics informed through preclinical infection systems, and return those findings to the bedside. Moreover, this approach would allow prospective identification and validation of optimal shorter therapeutic durations with new regimens. Optimized treatment using available and repurposed drugs may have an increased impact when prioritizing a person-centered approach and acknowledge the importance of age, gender, comorbidities, and both social and programmatic environments. In this viewpoint article, we present an in-depth discussion on how TB pharmacology and the related strategies will contribute to TB elimination.